Hubei Biocause Heilen Pharmaceutical Co. Ltd. Capital Reinvestment Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. capital reinvestment ratio. Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Capital Reinvestment Ratio of 1.44x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥11.57 Million) in capital expenditures (CN¥16.64 Million). See free cash flow generation of Hubei Biocause Heilen Pharmaceutical Co. to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Capital reinvestment ratio of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2018 to 2025. This chart tracks Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s Capital Reinvestment Ratio across 8 annual periods. See 301211 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Capital Reinvestment Ratio by Year (2018–2025)
Hubei Biocause Heilen Pharmaceutical Co. Ltd. capital reinvestment ratio by year from 2018 to 2025. For the full cash flow conversion analysis, see cash efficiency ratio of Hubei Biocause Heilen Pharmaceutical Co..
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 6.93x | CN¥7.55 Million | CN¥52.33 Million | ▲ +304.9% |
| 2024 | 1.71x | CN¥96.07 Million | CN¥164.43 Million | ▲ +25.8% |
| 2023 | 1.36x | CN¥137.06 Million | CN¥186.53 Million | ▲ +349.4% |
| 2022 | 0.30x | CN¥250.79 Million | CN¥75.95 Million | ▲ +78.2% |
| 2021 | 0.17x | CN¥123.98 Million | CN¥21.07 Million | ▲ +54.4% |
| 2020 | 0.11x | CN¥121.67 Million | CN¥13.39 Million | ▲ +26.7% |
| 2019 | 0.09x | CN¥372.33 Million | CN¥32.34 Million | ▼ -73.6% |
| 2018 | 0.33x | CN¥76.18 Million | CN¥25.08 Million | — |